Hospital
Mainehealth
Mainehealth was paid $31.54M by Medicaid between Jan 2018 and Dec 2024, across 416 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 34% of everything it billed.
33Billing provider infoMAINEHEALTH
ROCKPORT, ME 04856
ROCKPORT, ME 04856
33aNPI1982645305assigned 06/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$31.54M
24GClaims967,450
24DCodes billed416
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maine
Rank by total paid#8 of 33
Median peer was paid$4.34M
This provider vs. median7.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HUNTER, ROBERT controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 121,725 | $3.40M | |
| 2019 | 130,354 | $3.97M | |
| 2020 | 109,399 | $3.37M | |
| 2021 | 148,868 | $4.73M | |
| 2022 | 149,385 | $5.02M | |
| 2023 | 157,000 | $5.30M | |
| 2024incomplete | 150,719 | $5.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 34% | 157,022 | 119,176 | $10.87M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 19,489 | 17,547 | $3.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 4,766 | 4,496 | $1.59M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.7% | 11,102 | 10,622 | $1.49M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 6,792 | 6,093 | $708K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 7,724 | 7,296 | $668K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.0% | 15,179 | 3,994 | $646K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.7% | 13,897 | 13,596 | $532K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 3,620 | 3,503 | $442K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 1,253 | 1,240 | $414K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 18,015 | 7,295 | $375K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.2% | 12,677 | 5,030 | $371K |
404 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 3,966 | $341K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,111 | $301K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 4,996 | $300K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,101 | $290K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,587 | $285K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,498 | $276K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 514 | $273K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 9,472 | $270K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 4,235 | $260K |
| 20610 | <1% | 2,510 | $257K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 13,273 | $244K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 2,170 | $238K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 4,649 | $236K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,992 | $233K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,280 | $226K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,939 | $196K |
| G0008 | Administration of influenza virus vaccine | <1% | 8,290 | $195K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,988 | $194K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,969 | $193K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,672 | $190K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,511 | $182K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,135 | $181K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 14,682 | $158K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,233 | $156K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,200 | $148K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,140 | $144K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,380 | $126K |
| 94060 | <1% | 875 | $125K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,164 | $117K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,237 | $108K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,616 | $107K |
| 76830 | Ultrasound, transvaginal | <1% | 1,173 | $97K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,544 | $94K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 741 | $91K |
| 80061 | Lipid panel | <1% | 11,393 | $86K |
| 97161 | <1% | 2,572 | $86K | |
| 90677 | <1% | 1,044 | $84K | |
| 80053 | Comprehensive metabolic panel | <1% | 40,559 | $83K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,086 | $79K |
| 97162 | <1% | 1,837 | $65K | |
| 90837 | Psychotherapy session, about an hour | <1% | 652 | $62K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 755 | $60K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,757 | $56K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,555 | $56K |
| 86900 | <1% | 1,971 | $50K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 2,048 | $50K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,516 | $47K |
| 90686 | <1% | 8,472 | $46K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 37,648 | $46K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,674 | $45K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,150 | $45K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,895 | $44K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 550 | $44K |
| 71250 | <1% | 1,019 | $43K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 355 | $43K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 103 | $42K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 355 | $40K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 371 | $39K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 89 | $37K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,367 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,367 | $36K |
| 17110 | <1% | 608 | $35K | |
| 92557 | <1% | 470 | $33K | |
| 11102 | <1% | 295 | $33K | |
| 90651 | <1% | 2,170 | $33K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,397 | $31K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 86 | $31K |
| 70496 | <1% | 192 | $30K | |
| 91322 | <1% | 738 | $30K | |
| 11721 | <1% | 2,994 | $29K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,444 | $29K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,925 | $29K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,598 | $27K |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 1,394 | $27K |
| 93971 | <1% | 481 | $25K | |
| 97597 | <1% | 334 | $24K | |
| 97165 | <1% | 583 | $24K | |
| 82607 | <1% | 4,655 | $23K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,687 | $20K |
| 97116 | <1% | 1,491 | $19K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 216 | $19K |
| 93017 | <1% | 467 | $19K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 669 | $19K |
| 82728 | <1% | 3,857 | $19K | |
| 0001A | <1% | 601 | $18K | |
| 85027 | <1% | 10,628 | $18K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,411 | $18K |
| 99188 | <1% | 763 | $17K | |
| 0002A | <1% | 643 | $17K | |
| 94664 | <1% | 184 | $17K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,411 | $17K |
| 90732 | <1% | 318 | $16K | |
| D1206 | Topical application of fluoride varnish | <1% | 1,355 | $16K |
| 0012A | <1% | 743 | $16K | |
| 76801 | <1% | 180 | $16K | |
| 72100 | <1% | 771 | $15K | |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 49 | $15K |
| 11056 | <1% | 376 | $15K | |
| 95908 | <1% | 88 | $15K | |
| 97035 | <1% | 2,854 | $15K | |
| 88142 | <1% | 1,551 | $15K | |
| 0011A | <1% | 776 | $14K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 47 | $14K |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 760 | $13K |
| 86780 | <1% | 1,162 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,880 | $13K |
| 36591 | <1% | 607 | $12K | |
| 86618 | <1% | 3,327 | $12K | |
| 97113 | <1% | 123 | $12K | |
| 90480 | <1% | 880 | $12K | |
| 87481 | <1% | 2,126 | $12K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 50 | $12K |
| 86803 | <1% | 2,883 | $12K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 50 | $12K |
| 73562 | <1% | 1,953 | $11K | |
| 83655 | <1% | 1,948 | $11K | |
| 82746 | <1% | 2,319 | $11K | |
| 85610 | <1% | 13,985 | $10K | |
| 84439 | <1% | 2,409 | $10K | |
| 83550 | <1% | 3,575 | $10K | |
| 92523 | <1% | 74 | $10K | |
| 90688 | <1% | 941 | $9K | |
| 73030 | <1% | 1,813 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,747 | $9K |
| 95910 | <1% | 47 | $8K | |
| 73630 | <1% | 1,628 | $8K | |
| 83540 | <1% | 3,737 | $8K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 58 | $8K |
| 96415 | <1% | 168 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 270 | $7K |
| Q3014 | Telehealth originating site facility fee | <1% | 484 | $7K |
| 73502 | <1% | 1,148 | $7K | |
| 90670 | <1% | 2,627 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 899 | $7K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 138 | $7K |
| 84702 | <1% | 944 | $6K | |
| 0031A | <1% | 258 | $6K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 66 | $6K |
| 87511 | <1% | 1,093 | $6K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,680 | $6K |
| 0064A | <1% | 900 | $6K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 430 | $6K |
| 83970 | <1% | 509 | $6K | |
| 90656 | <1% | 714 | $5K | |
| 86140 | <1% | 5,745 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,107 | $5K |
| 73610 | <1% | 1,324 | $5K | |
| 87468 | <1% | 996 | $5K | |
| 87469 | <1% | 996 | $5K | |
| 76642 | <1% | 102 | $5K | |
| 72141 | <1% | 54 | $5K | |
| 0124A | <1% | 429 | $5K | |
| 0054A | <1% | 250 | $5K | |
| 73110 | <1% | 984 | $5K | |
| 73130 | <1% | 915 | $5K | |
| 83880 | <1% | 3,007 | $5K | |
| 0134A | <1% | 432 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,933 | $5K |
| 84153 | <1% | 777 | $5K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 261 | $5K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 34 | $5K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 186 | $4K |
| 83735 | <1% | 6,212 | $4K | |
| 82784 | <1% | 1,227 | $4K | |
| 87070 | <1% | 5,325 | $4K | |
| 84403 | <1% | 270 | $4K | |
| 87186 | <1% | 3,411 | $4K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 13 | $4K |
| 73221 | <1% | 26 | $4K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $4K |
| 82043 | <1% | 2,473 | $3K | |
| 81001 | <1% | 9,165 | $3K | |
| 31575 | <1% | 39 | $3K | |
| D0191 | <1% | 80 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 144 | $3K |
| 92587 | <1% | 12 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 123 | $3K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 374 | $3K |
| 87340 | <1% | 1,335 | $3K | |
| 87077 | <1% | 3,537 | $3K | |
| 69210 | <1% | 188 | $3K | |
| 86038 | <1% | 619 | $3K | |
| 90734 | <1% | 1,734 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 978 | $3K |
| 85651 | <1% | 2,549 | $3K | |
| 70498 | <1% | 255 | $2K | |
| 93242 | <1% | 272 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 142 | $2K |
| 80076 | <1% | 674 | $2K | |
| 76775 | <1% | 42 | $2K | |
| 99495 | <1% | 37 | $2K | |
| 80050 | General health panel | <1% | 80 | $2K |
| 83516 | <1% | 441 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,302 | $2K |
| 90662 | <1% | 657 | $2K | |
| 83690 | <1% | 4,513 | $2K | |
| 10060 | <1% | 14 | $2K | |
| 85018 | <1% | 2,267 | $2K | |
| 97803 | <1% | 46 | $1K | |
| 20553 | <1% | 13 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 172 | $1K |
| 74018 | <1% | 54 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,288 | $1K |
| 84100 | <1% | 1,341 | $1K | |
| 0013A | <1% | 50 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 18 | $1K |
| 86617 | <1% | 306 | $1K | |
| 99406 | <1% | 66 | $1K | |
| 96127 | <1% | 113 | $1K | |
| 82570 | <1% | 613 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,265 | $1K |
| 17000 | <1% | 39 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 39 | $1K |
| 96367 | <1% | 29 | $1K | |
| 81003 | <1% | 5,482 | $960.24 | |
| 92567 | <1% | 824 | $929.86 | |
| 82565 | <1% | 748 | $911.87 | |
| 93923 | <1% | 12 | $907.45 | |
| 86364 | <1% | 221 | $882.24 | |
| 80069 | <1% | 244 | $875.89 | |
| 76536 | <1% | 12 | $858.66 | |
| 86706 | <1% | 209 | $842.73 | |
| 84703 | <1% | 3,663 | $838.16 | |
| 82550 | <1% | 891 | $825.02 | |
| 81025 | <1% | 1,005 | $816.93 | |
| 90716 | <1% | 388 | $816.70 | |
| 85652 | <1% | 980 | $806.17 | |
| 11719 | <1% | 75 | $798.12 | |
| 86003 | <1% | 26 | $772.77 | |
| 99496 | <1% | 17 | $767.76 | |
| 77080 | <1% | 38 | $765.82 | |
| G0378 | Hospital observation service, per hour | <1% | 1,437 | $757.51 |
| 71271 | <1% | 12 | $750.06 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 28 | $720.63 |
| 73140 | <1% | 74 | $715.29 | |
| 82950 | <1% | 136 | $712.83 | |
| 86141 | <1% | 119 | $698.62 | |
| 0004A | <1% | 286 | $691.32 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 28 | $690.99 |
| 73080 | <1% | 104 | $671.93 | |
| 97802 | <1% | 13 | $666.06 | |
| 87040 | <1% | 1,704 | $665.83 | |
| 81002 | <1% | 3,803 | $658.04 | |
| 84484 | <1% | 8,376 | $643.55 | |
| 88342 | <1% | 202 | $639.11 | |
| 0072A | <1% | 232 | $637.01 | |
| 84156 | <1% | 561 | $604.03 | |
| 94726 | <1% | 68 | $584.83 | |
| 85379 | <1% | 1,171 | $548.44 | |
| 84550 | <1% | 782 | $538.07 | |
| 80305 | <1% | 729 | $524.74 | |
| 86762 | <1% | 281 | $521.61 | |
| 80164 | <1% | 170 | $507.50 | |
| 11720 | <1% | 68 | $497.63 | |
| 11055 | <1% | 26 | $485.38 | |
| 83615 | <1% | 511 | $480.78 | |
| 87205 | <1% | 1,075 | $463.98 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 15 | $452.34 |
| 86704 | <1% | 148 | $451.73 | |
| 84460 | <1% | 375 | $420.35 | |
| 0052A | <1% | 12 | $406.78 | |
| 86431 | <1% | 196 | $404.96 | |
| 82040 | <1% | 550 | $401.21 | |
| 93225 | <1% | 12 | $396.24 | |
| S9441 | Asthma education, non-physician provider, per session | <1% | 27 | $386.91 |
| 86850 | <1% | 1,978 | $377.73 | |
| 86480 | <1% | 13 | $371.88 | |
| 69209 | <1% | 24 | $355.02 | |
| 84425 | <1% | 24 | $325.14 | |
| 85730 | <1% | 537 | $316.72 | |
| 90715 | <1% | 3,234 | $300.28 | |
| 84450 | <1% | 267 | $293.45 | |
| 93246 | <1% | 28 | $283.00 | |
| 51702 | <1% | 25 | $265.79 | |
| 70486 | <1% | 12 | $240.79 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 45 | $236.25 |
| J2704 | Injection, propofol, 10 mg | <1% | 6,419 | $234.14 |
| 83993 | <1% | 15 | $215.93 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,146 | $213.69 |
| 85014 | <1% | 375 | $213.57 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 100 | $212.96 |
| 84165 | <1% | 117 | $211.82 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,065 | $195.20 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,180 | $192.07 |
| 73560 | <1% | 35 | $186.97 | |
| 83605 | <1% | 2,674 | $183.32 | |
| 84402 | <1% | 17 | $183.06 | |
| 96381 | <1% | 13 | $172.64 | |
| 84480 | <1% | 14 | $159.39 | |
| 80178 | <1% | 39 | $153.35 | |
| 83001 | <1% | 12 | $133.85 | |
| 82805 | <1% | 1,035 | $124.60 | |
| 82105 | <1% | 13 | $117.39 | |
| 86376 | <1% | 12 | $103.16 | |
| 84207 | <1% | 12 | $99.70 | |
| 88720 | <1% | 99 | $95.60 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 26 | $93.68 |
| 0071A | <1% | 234 | $85.29 | |
| 86901 | <1% | 2,080 | $76.33 | |
| 83721 | <1% | 26 | $76.09 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,339 | $67.20 |
| 82948 | <1% | 4,379 | $61.86 | |
| 87634 | <1% | 16 | $60.66 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,353 | $60.65 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,190 | $56.74 |
| 51798 | <1% | 41 | $49.61 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 868 | $44.86 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,117 | $42.89 |
| 95886 | <1% | 477 | $41.20 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 482 | $39.21 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 641 | $35.52 |
| C9399 | Unclassified drugs or biologicals | <1% | 72 | $25.07 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 716 | $24.00 |
| 85045 | <1% | 18 | $23.94 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 248 | $22.21 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 14 | $18.74 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,546 | $17.14 |
| 96376 | <1% | 1,092 | $15.84 | |
| 86787 | <1% | 14 | $12.88 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 325 | $12.74 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 257 | $10.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,358 | $9.00 |
| 81000 | <1% | 18 | $6.48 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 393 | $5.78 |
| 84520 | <1% | 12 | $3.95 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 853 | $2.58 |
| 98928 | <1% | 13 | $1.28 | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 14 | $0.10 |
| 90723 | <1% | 1,358 | $0.01 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,646 | $0.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 7,353 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 509 | $0.00 |
| 91313 | 0% | 206 | $0.00 | |
| 90710 | 0% | 1,038 | $0.00 | |
| 87420 | 0% | 96 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 592 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 38 | $0.00 |
| 90681 | 0% | 1,039 | $0.00 | |
| 76376 | 0% | 329 | $0.00 | |
| 90707 | 0% | 328 | $0.00 | |
| 90700 | 0% | 588 | $0.00 | |
| 90633 | 0% | 2,040 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 379 | $0.00 |
| 91321 | 0% | 99 | $0.00 | |
| 91312 | 0% | 234 | $0.00 | |
| 90685 | 0% | 369 | $0.00 | |
| 91300 | 0% | 1,023 | $0.00 | |
| 94729 | 0% | 460 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 382 | $0.00 |
| 94727 | 0% | 306 | $0.00 | |
| 90671 | 0% | 108 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 280 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 293 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 29 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 48 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 15 | $0.00 |
| 91311 | 0% | 41 | $0.00 | |
| 93356 | 0% | 88 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 26 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 47 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 26 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 14 | $0.00 |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 0% | 14 | $0.00 |
| 90713 | 0% | 18 | $0.00 | |
| 0003A | 0% | 12 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 401 | $0.00 |
| 91303 | 0% | 162 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 846 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 878 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 111 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 187 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 186 | $0.00 |
| 90474 | 0% | 1,509 | $0.00 | |
| 90696 | 0% | 608 | $0.00 | |
| 90697 | 0% | 877 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 543 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 245 | $0.00 |
| 90647 | 0% | 1,405 | $0.00 | |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 0% | 521 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 106 | $0.00 |
| 91305 | 0% | 270 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,864 | $0.00 |
| 91301 | 0% | 829 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 276 | $0.00 |
| 90680 | 0% | 463 | $0.00 | |
| 88304 | 0% | 26 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 159 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 287 | $0.00 |
| 91306 | 0% | 423 | $0.00 | |
| 36416 | 0% | 82 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 75 | $0.00 |
| 0399T | 0% | 74 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 12 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 56 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 14 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 34 | $0.00 |
| 91307 | 0% | 376 | $0.00 | |
| 94761 | 0% | 12 | $0.00 | |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 36 | $0.00 |
| 90619 | 0% | 15 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 19 | $0.00 |
| 12001 | 0% | 12 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUNTER, ROBERT (SENIOR VICE PRESIDENT - FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Mainehealth | Farmington, ME | $16.71M |
| Mainehealth | Norway, ME | $10.00M |
| Mainehealth | Norway, ME | $9.84M |
| Mainehealth | Damariscotta, ME | $9.60M |
| Mainehealth | Belfast, ME | $5.33M |
| Mainehealth | Norway, ME | $5.06M |
| Mainehealth | Livermore Falls, ME | $3.15M |
| Mainehealth | Boothbay Harbor, ME | $2.90M |
| Mainehealth | Damariscotta, ME | $2.62M |
| Mainehealth | Farmington, ME | $2.36M |
| University Pathologists | Houston, TX | $1.35M |
| Mainehealth | Farmington, ME | $435K |
| P R Hematology Oncology Group INC | Bayamon, PR | $69K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.